-
Transmission of SARS-CoV-2 (COVID-19) via Droplets and Aerosols (Post)
Transmission of SARS-CoV-2 (COVID-19) via Droplets and Aerosols What is COVID-19? COVID-19, the disea
Antibody Seroconversion Response in COVID-19(Post)Seroconversion Implications in SARS-CoV-2 Diagnostic Testing Key Points: COVID-19, the pandemic
Hybridoma Technology: Revolutionizing Antibody Production(Post)Immunology · Antibody ProductionHybridoma Technology: How Monoclonal Antibodies Are MadeHybridoma technology, pioneered by Georges Köhler and César Milstein in 1975, is the method that made monoclonal
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
Biomarkers & Inflammatory markers of atherosclerosis(Post)As atherosclerosis is a complex inflammatory disease, there are many influential biomarkers that contribute to the disease’s progression as well as biomarkers from atherosclerosis related di
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
COVID-19(SARS-CoV-2)トリプレックスRT-qPCR検出キット| Assay Genie(Post)COVID-19(SARS-CoV-2)トリプレックスRT-qPCR検出キット COVID-19アッセイの概要: この製品は、新規コロナウイルスSARS-CoV-2によって引き
Co-Immunoprecipitation (co-IP) Protocol - Mandarin(Page)共免疫沉淀(Co-IP)方案(中文) | Assay Genie
Complement: The Brake Matters More Than the Trigger(Post)Complement is firing on your own cells right now. Not in response to anything — C3 hydrolyses spontaneously in plasma at a low, constant rate, and every hydrolysed molecule is a potential convertase
Kundenspezifischer ELISA für Forschende, Checkliste und 4–12 Wochen(Post)Ein kundenspezifischer ELISA ist die richtige Wahl, wenn kein Katalogkit Ihre Zielmatrix, Spezies oder Sensitivität abdeckt. Am Ende steht kein Standardprodukt, sondern ein validierter Assay mit d
VEGF-A VEGFR-2 Signaling: Decoding the Blueprint of Angiogenesis for Therapeutic Insights(Post)The orchestration of angiogenesis, the process by which new blood vessels form from pre-existing ones, is a complex symphony regulated by various molecular players. At the forefront of this int
Everything You Need to Know About Preeclampsia: A Guide(Post)Preeclampsia is a serious condition that can develop during pregnancy. It is marked by high blood pressure and the presence of protein in the urine and can cause serious problems for b
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Antibody-Drug Conjugates: Internalisation, Trafficking & the Bystander Effect(Page) Complete T Helper Cell Guide: Th1, Th2, Th17 & Functions(Post)The Th1 Pathway In this guide, we will explore the differences between TH1 and TH2 cells, their crucial roles in the immune system, and the contributions of cytokines and transcription f
GITR: Boosting T Cell Activation for Enhanced Cancer Immunotherapy(Post)Glucocorticoid-induced tumor necrosis factor receptor (GITR) is an immune checkpoint molecule that plays a crucial role in regulating T cell activation and survival. In recent years, GITR
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest